SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 2025.
  • 2
    Ware JE, Snow KK, Kosinski M. SF36 Health Survey: manual and interpretation guide. Lincoln (RI): QualityMetric Incorporated; 2000.
  • 3
    Maddison P. Prevention of vascular damage in scleroderma with angiotensin-converting enzyme (ACE) inhibition. Rheumatology (Oxford) 2002; 41: 96571.
  • 4
    Brennan P, Silman A, Black C, Bernstein R, Coppock J, Maddison P, et al, and the UK Scleroderma Study Group. Reliability of skin involvement measures in scleroderma. Br J Rheumatol 1992; 31: 45760.
  • 5
    Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26: 215967.
  • 6
    Ware JE, Kosinski M. SF-36 physical and mental health summary scales: a manual for users of version 1. 2nd ed. Lincoln (RI): QualityMetric Incorporated; 2001.
  • 7
    National Assembly for Wales. Welsh Health Survey. London: Her Majesty's Stationery Office; 1998.
  • 8
    Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 1999; 42: 26605.
  • 9
    Seibold JR, McCloskey DA. Skin involvement as a relevant outcome measure in clinical trials of systemic sclerosis. Curr Opin Rheumatol 1997; 9: 5715.
  • 10
    Grabowski G, Grant JP. Nutritional support in patients with systemic scleroderma. JPEN J Parenter Enteral Nutr 1989; 13: 14751.
  • 11
    Tomaino MM, Goitz RJ, Medsger TA. Surgery for ischemic pain and Raynaud's phenomenon in scleroderma: a description of treatment protocol and evaluation of results. Microsurgery 2001; 21: 759.
  • 12
    Muellegger RR, Hofer A, Salmhofer W, Soyer HP, Kerl H, Wolf P. Extended extracorporeal photochemotherapy with extracorporeal administration of 8-methoxypsoralen in systemic sclerosis: an Austrian single-center study. Photodermatol Photoimmunol Photomed 2000; 16: 21623.
  • 13
    Poole JL, Williams CA, Bloch DA, Hollak B, Spitz P. Concurrent validity of the Health Assessment Questionnaire Disability Index in scleroderma. Arthritis Care Res 1995; 8: 18993.
  • 14
    Sultan N, Pope JE, Clements PJ, and the Scleroderma Trials Study Group. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma. Rheumatology (Oxford) 2004; 43: 4728.
  • 15
    Ruof J, Bruhlmann P, Michel BA, Stucki G. Development and validation of a self-administered systemic sclerosis questionnaire (SySQ). Rheumatology (Oxford) 1999; 38: 53542.
  • 16
    Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997; 40: 198491.
  • 17
    Oelzner S, Schmidt S, Looks A, Lange D, Oelzner P, Hein G, et al. Explorative study on quality of life in patients with progressive-systemic scleroderma. Aktuelle Derm 1999; 25: 12932. In German.
  • 18
    Grassegger A, Schuler G, Hessenberger G, Walder-Hantich B, Jabkowski J, MacHeiner W, et al. Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol 1998; 139: 63948.
  • 19
    Benrud-Larson LM, Haythornthwaite JA, Heinberg LJ, Boling C, Reed J, White B, et al. The impact of pain and symptoms of depression in scleroderma. Pain 2002; 95: 26775.
  • 20
    Pincus T, Swearingen C, Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 1999; 42: 222030.
  • 21
    Covinsky KE, Wu AW, Landefeld CS, Connors AF Jr, Phillips RS, Tsevat J, et al. Health status versus quality of life in older patients: does the distinction matter? Am J Med 1999; 106: 43540.
  • 22
    Enomoto DN, Mekkes JR, Bossuyt PM, Yong SL, Out TA, Hoekzema R, et al. Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). J Am Acad Dermatol 1999; 41: 91522.
  • 23
    Georges C, Chassany O, Mouthon L, Tiev K, Marjanovic Z, Meyer O, et al. Quality of life assessment with the MOS-SF36 in patients with systemic sclerosis. Rev Med Interne 2004; 25: 1621. In French.
  • 24
    Del Rosso A, Boldrini M, D'Agostino D, Placidi GP, Scarpato A, Pignone A, et al. Health-related quality of life in systemic sclerosis as measured by the Short Form 36: relationship with clinical and biologic markers. Arthritis Rheum 2004; 51: 47581.
  • 25
    Cossutta R, Zeni S, Soldi A, Colombelli P, Belotti Masserini A, Fantini F. Evaluation of quality of life in patients with systemic sclerosis by administering the SF-36 questionnaire. Reumatismo 2002; 54: 1227. In Italian.
  • 26
    Kenefick NJ, Vaizey CJ, Cohen RC, Nicholls RJ, Kamm MA. Medium-term results of permanent sacral nerve stimulation for faecal incontinence. Br J Surg 2002; 89: 896901.
  • 27
    Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, et al. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005; 52: 592600.
  • 28
    Danieli E, Airo P, Bettoni L, Cinquini M, Antonioli CM, Cavazzana I, et al. Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol 2005; 24: 4854.
  • 29
    Bowling A. Measuring health: a review of quality of life measurement scales. Milton Keynes: Open University Press; 1991.
  • 30
    Health Survey for England in 1996. London: The Stationery Office; 1998.
  • 31
    Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992; 305: 1604.
  • 32
    Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 1993; 306: 143740.
  • 33
    Sandqvist G, Eklund M, Akesson A, Nordenskiold U. Daily activities and hand function in women with scleroderma. Scand J Rheumatol 2004; 33: 1027.
  • 34
    Nietert PJ, Mitchell HC, Bolster MB, Curran MY, Tilley BC, Silver RM. Correlates of depression, including overall and gastrointestinal functional status, among patients with systemic sclerosis. J Rheumatol 2005; 32: 517.
  • 35
    Ruta DA, Hurst NP, Kind P, Hunter M, Stubbings A. Measuring health status in British patients with rheumatoid arthritis: reliability, validity and responsiveness of the short form 36-item health survey (SF-36). Br J Rheumatol 1998; 37: 42536.
  • 36
    Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE Jr, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care 2002; 8: 23140.
  • 37
    Panopalis P, Petri M, Manzi S, Isenberg DA, Gordon C, Senecal JL, et al. The systemic lupus erythematosus tri-nation study: longitudinal changes in physical and mental well-being. Rheumatology (Oxford) 2005; 44: 7515.